Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts

Anna V. Naumova, Vadappuram P. Chacko, Ronald Ouwerkerk, Linda Stull, Eduardo Marbán and Robert G. Weiss

doi:10.1152/ajpheart.00831.2005

You might find this additional information useful...

This article cites 49 articles, 27 of which you can access free at:
http://ajpheart.physiology.org/cgi/content/full/290/2/H837#BIBL

This article has been cited by 2 other HighWire hosted articles:

Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol
P. Pacher, A. Nivorozhkin and C. Szabo
[Abstract] [Full Text] [PDF]

Xanthine Oxidase Inhibition and Heart Failure: Novel Therapeutic Strategy for Ventricular Dysfunction?
R. J. Hajjar and J. A. Leopold
[Full Text] [PDF]

Updated information and services including high-resolution figures, can be found at:
http://ajpheart.physiology.org/cgi/content/full/290/2/H837

Additional material and information about AJP - Heart and Circulatory Physiology can be found at:
http://www.the-aps.org/publications/ajpheart

This information is current as of September 7, 2006.
Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts

Anna V. Naumova, Vadappuram P. Chacko, Ronald Ouwerkerk, Linda Stull, Eduardo Marbán, and Robert G. Weiss

Department of Radiology, Division of Magnetic Resonance Research, and Department of Pediatrics, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Medicine, Division of Cardiology, the Johns Hopkins Hospital, Baltimore, Maryland

Submitted 4 August 2005; accepted in final form 6 September 2005

Ventricular remodeling occurs after myocardial infarction (MI) in many species, including humans, and is typically characterized by progressive ventricular dilatation, eccentric hypertrophy, and contractile dysfunction (27, 36, 38). Patients with post-MI remodeling experience increased rates of heart failure and cardiovascular mortality, whereas interventions that reduce geometric ventricular remodeling improve outcomes (27, 40, 41, 44). In addition to the geometric and contractile abnormalities associated with post-MI remodeling, adverse changes in energy metabolism also occur (15, 29, 32).

Abnormalities in energy metabolism after MI include reductions in ATP, phosphocreatine (PCr), and in the activity of the creatine kinase (CK) reaction, the primary energy reserve reaction of the heart (20, 21, 29, 31). Inhibitors of CK significantly increase mortality after experimental infarction (16). The reduction in cardiac PCr-to-ATP ratio (PCr/ATP) in experimental postinfarction remodeling is similar to that observed in human heart failure, which, in turn, correlates with clinical severity and predicts overall and cardiovascular mortality (4, 10, 15, 31, 34, 49). Taken together, the energetic consequences of post-MI remodeling are similar to those of heart failure and offer an additional potential mechanism that may contribute to progressive dysfunction and geometric changes.

Xanthine oxidase (XO) is important in purine metabolism, and its expression and activity are increased in heart failure (1). XO is also a major source of free radicals, such as superoxide, that can impair energy metabolism and reduce energetic efficiency (7, 11). In nonischemic experimental and human heart failure, inhibition of XO improves mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand (7, 11). Targeted XO blockade impacts on the progression of nonischemic cardiomyopathy in mice (43) and attenuates left ventricular (LV) remodeling processes after experimental MI (12). Despite the evidence for improved mechanoenergetic coupling with XO inhibition in nonischemic heart failure, the metabolic and contractile effects of XO inhibition on postinfarction remodeling and the effects of XO inhibitors (XOIs) on depressed energetics in failing hearts have not been characterized.

There were two aims to this study. The first aim was to determine the extent to which geometric, contractile, and metabolic remodeling occur in vivo after nonreperfused MI in the mouse. The second aim was to test the hypothesis that XOIs improve bioenergetics and contractile function in the failing heart. This is based on the mechanism observed in nonischemic heart failure where XOIs improve mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand, such that improved energetics, as indexed by the cardiac PCr/ATP, would be expected to be associated with improved contractile function.

MATERIALS AND METHODS

All procedures and protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
**MI in mice.** Anesthesia was induced in adult mice (20–30 g) by inhalation of methoxyflurane and maintained with intraperitoneal injection of etomidate (20 mg/kg) and with subcutaneous buprenorphine (0.24 mg/kg). Additional doses of etomidate were administered as needed. Mice were intubated and ventilated with a custom-made ventilator, and the body temperature was maintained constant as monitored with a rectal probe. A left thoracotomy and pericardiotomy were performed, and the left main coronary artery was completely ligated with suture. After verification that coronary occlusion had occurred by blanching of the tissue distal to the suture, the ribs were closed with suture and the mice recovered. Additional doses of buprenorphine (0.96 mg/kg) were administered to limit discomfort. Immediately after MI surgery, XO-inhibited mice received either allopurinol (0.5 mM) or oxypurinol (1 mM) in the drinking water, whereas control animals had neither. These concentrations were previously shown to inhibit XO in this model (43). Because few pharmacological agents are completely specific, we studied both allopurinol and oxypurinol to increase the likelihood that any observed metabolic or contractile effects were due to XO inhibition and not due to another effect of one agent. All animals underwent MRI and magnetic resonance (MR) spectroscopy (MRS) studies 4 wk after surgery.

**MRI and MRS.** Experiments were performed by using a General Electric Omega NMR spectrometer and Bruker Medical BioSpec Spectrometer (Bruker BioSpin) equipped with a 4.7 T/40 cm Oxford magnet and a 15 cm (ID) actively shielded Accustar gradient set (8, 47).

Mice were anesthetized with 1% isoflurane in oxygen (1 l/min) delivered through a nose cone and placed in a custom-constructed 1H coil with the heart centered over the 31P coil (8, 47) on a flat Plexiglas platform with temperature control (37 ± 1°C). The mice were rotated to the left so that the uninvolved septum was centered over the surface coil, thus minimizing contributions from the infarcted lateral wall. Single-lead ECG was recorded from platinum electrodes attached to each animal’s extremities and was used to trigger the MRI acquisitions using commercial software (Small Animal Monitoring and Gating System SA Instrument, Stony Brook, NY).

High-resolution, spin-echo transverse 1H MR images (echo time, 11 ms; recycle time, 500 ms; slice thickness, 2 mm; field of view, 32 mm; and acquisition time, 2 min) were obtained to define the regions of metabolic interest, as well as to confirm the position of the LV over the center of the 31P MRS surface coil (11 mm, OD), and to quantify LV function. A set of multi-slice short-axis images (slice thickness, 1.2 mm without gap between slices) for end systole and another for end diastole were acquired. Each slice was acquired exactly at the same time during R-R interval in cardiac cycle. Epicardial and endocardial borders were manually delineated for determination of LV volumes at end systole and end diastole (ESV and EDV, respectively) and LV mass using the software package National Institutes of Health (NIH) Image version 1.52 (Bethesda, MD) for a Macintosh computer. Total LV volumes were calculated as the sum of all slice volumes. Stroke volume (SV) was calculated as EDV minus ESV and cardiac output as SV multiplied by heart rate. The LV ejection fraction (EF) was calculated from the relative difference in EDV and ESV.

Myocardial infarct size was determined from short-axis systolic images. The circumference of the LV that was thinned due to infarction (systolic wall thickness <0.5 mm) was compared with that of viable tissue, and a score was assigned as a percentage of overall ventricular circumference (14). For each heart, the mean score was determined from all of the image slices.

Spatially localized 31P MR spectra were acquired after optimization of the magnetic field homogeneity using the 1H coil to shim on a thick slice containing the heart. A one-dimensional chemical shift imaging sequence was used with 32 phase-encode steps in the direction perpendicular to the plane of the coil. The time of the phase-encode gradient was 0.5 ms, the field of view 32 mm, the recycle delay 1 s, and 64 averages were obtained per phase-encode step. Adiabatic pulses with a flip angle of 45° were used for uniform excitation. Total acquisition time was ~34 min. With this protocol, well-resolved spectra from 1-mm slices from the antero-septal region of the mouse heart parallel to the coil were obtained (8, 47). In a prior study (47) these noninvasive image-guided 31P MRS techniques gave identical results to those obtained from invasive measures, indicating minimal contamination from surrounding structures with this approach (47). All mice awoke within ~1 min after completing the MRI/MRS examination.

31P spectra were analyzed with a combination of custom (3) and proprietary (NIH Image, Bethesda, MD) software. The PCR/ATP was determined from the integrated peak areas of the PCr and [β-P]ATP resonances from voxels centered on skeletal muscle in the anterior chest or on cardiac muscle identified from the high-resolution 1H MR images, as described previously (8). Voxel shifting was performed when necessary to optimize slice alignment with cardiac structures and to minimize skeletal muscle contamination of cardiac spectra (5). The PCR/ATP values were corrected for partial saturation effects using a factor determined in separate studies (6, 8, 46, 47) that included fully relaxed acquisitions. Infarcted, nonviable myocardium lacks PCR and ATP (45, 48). In prior 31P MRS studies (16, 18, 19, 32, 33, 37) of infarcted rodent hearts, the detected PCR and ATP signals were attributed to the surviving viable regions, even when the entire infarcted region was contained within the region studied by MRS. Based on this accepted practice and our efforts through animal positioning and slice selection to minimize infarcted tissue within the volume of interest, the cardiac PCR/ATP values reported here derive almost entirely from surviving, viable myocardium. Data were compared by ANOVA with STATISTICA software (StatSoft, Tulsa, OK). Differences were considered statistically significant at P < 0.05. All data means ± SD.

**RESULTS**

Postinfarction remodeling in mice. The mean body weight for all animals was 29 ± 2 g, and there were no statistically significant differences among the groups. There were no significant anatomic, functional, or metabolic differences between allopurinol- and oxypurinol-treated hearts, so the groups were combined (MI+XOI) (Table 1).

Representative 1H MR cardiac images acquired at end systole and end diastole are shown in Fig. 1 for a normal mouse (control) and in another after MI. Four weeks after MI, there was a significant increase in mean LV mass, a severalfold increase in LV chamber dimensions, and a significant reduction in EF, as shown in Table 1. Specifically, LV end-diastolic and end-systolic dimensions were increased by more than sixfold, and mean LV ejection fraction decreased from ~60% to 15% (Table 1). After infarction, LV mass doubled (P < 0.001) and the ratio of myocardial mass-to-chamber volume was reduced severalfold (P < 0.001, Table 1), consistent with prior observations (36, 38) in infarct-remodeled hearts. Together, these findings in MI mice demonstrate a marked degree of geometric remodeling and LV dysfunction that occurs in this model of permanent left main coronary artery occlusion.

To determine whether myocardium remote from infarction demonstrates energetic abnormalities in the mouse similar to those observed in larger animals, we used noninvasive image-guided 31P MRS to quantify cardiac high-energy phosphates. Representative in vivo cardiac 31P MR spectra from normal and infarct animals are shown in Fig. 2. In control mice, the mean PCr/ATP is 3.0 ± 0.6 in chest skeletal muscle and 2.1 ± 0.5 in heart. These agree well with previously published values in mice (8, 47), as well as those in larger species, including...
Table 1. $^1$H MR imaging results

<table>
<thead>
<tr>
<th>Group</th>
<th>$n$</th>
<th>ESV, mm$^3$</th>
<th>EDV, mm$^3$</th>
<th>SV, mm$^3$</th>
<th>CO, mm$^3$/min</th>
<th>LV mass, mg</th>
<th>LV mass/ESV, mg/mm$^3$</th>
<th>LV mass/EDV, mg/mm$^3$</th>
<th>MI size, %</th>
<th>EF, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control mice without MI</td>
<td>9</td>
<td>13±5</td>
<td>31±7</td>
<td>18±2</td>
<td>8,900±1,500</td>
<td>80±11</td>
<td>6.8±2.2</td>
<td>2.6±0.4</td>
<td>59±8</td>
<td></td>
</tr>
<tr>
<td>MI group, 4 wk after surgery</td>
<td>11</td>
<td>182±129*</td>
<td>203±133*</td>
<td>21±9</td>
<td>9,600±4,700</td>
<td>162±29*</td>
<td>1.4±0.9</td>
<td>1.2±0.7</td>
<td>55±11</td>
<td>14±9*</td>
</tr>
<tr>
<td>MI mice + allopurinol, 0.5 mM</td>
<td>7</td>
<td>84±29*</td>
<td>108±36*</td>
<td>23±11</td>
<td>10,500±49,000</td>
<td>139±16*</td>
<td>1.8±0.6</td>
<td>1.4±0.5</td>
<td>48±8</td>
<td>21±7*</td>
</tr>
<tr>
<td>MI mice + oxyurinol, 1 mM</td>
<td>11</td>
<td>104±66*</td>
<td>131±75*</td>
<td>28±14</td>
<td>13,200±7,300</td>
<td>159±32*</td>
<td>2.0±0.9</td>
<td>1.4±0.9</td>
<td>50±9</td>
<td>24±10*</td>
</tr>
<tr>
<td>XOIs, allopurinol and oxyurinol combined</td>
<td>18</td>
<td>96±54*‡</td>
<td>122±62*‡</td>
<td>26±13</td>
<td>12,200±6,400</td>
<td>151±28*</td>
<td>1.9±0.8</td>
<td>1.4±0.5</td>
<td>49±9</td>
<td>23±9*§</td>
</tr>
</tbody>
</table>

Values are means ± SD; $n$ = number of mice. MR, magnetic resonance; ESV, end-systolic volume; EDV, end-diastolic volume; SV, stroke volume; CO, cardiac output; LV, left ventricular; MI, myocardial infarction; EF, ejection fraction; XOIs, xanthine oxidase inhibitors. *$P < 0.005$ vs. normal control mice; †$P < 0.08$ vs. MI group; ‡$P < 0.03$ vs. MI group; §$P < 0.01$ vs. MI group.

Humans (6, 26, 46). In contrast, infarct remodeled myocardium is characterized by a significant 30% decrease in the mean cardiac PCr/ATP to 1.4 ± 0.6 ($P < 0.02$).

**Effects of XOIs in remodeled mouse myocardium.** XO therapy did not affect the increase in LV mass that develops after infarction but did significantly attenuate the marked degree of ventricular dilatation that occurs (Table 1). Specifically, XOIs attenuated the dramatic increase in ESV ($P = 0.02$) and EDV ($P = 0.03$) after infarction (Table 1). In addition, LV EF was significantly higher in all MI+XOI hearts (23 ± 9%) than in MI hearts (14 ± 9%, $P = 0.01$). Infarct size did not significantly differ between control and XOIs hearts (55 ± 11% and 49 ± 9%, respectively; $P = 0.10$, Table 1), in accord with prior histopathological findings in this model (43).

XO inhibition with allopurinol and oxyurinol after infarction normalized myocardial PCr/ATP (Fig. 3). The mean myocardial PCr-to-ATP ratios were 2.1 ± 0.7 and 1.9 ± 0.4 for allopurinol and oxyurinol, respectively. The cardiac PCr/ATP was significantly higher in MI+XOI (2.0 ± 0.5) than in MI mice (1.4 ± 0.6, $P < 0.04$) and similar to that in normal, noninfarcted mice.

There was a correlation between the metabolic and functional parameters in MI and MI+XOI hearts (Fig. 4) in that the correlation coefficient between PCr/ATP and ESV was −0.7 ($P < 0.05$) and between PCr/ATP and EF, $r = 0.65$ ($P < 0.05$). Thus XO inhibition normalizes the reduced cardiac PCr/ATP in these failing, infarct-remodeled mouse hearts, and this is associated with improved contractile function.

**DISCUSSION**

The geometric, functional, and energetic consequences of post-MI remodeling were noninvasively characterized in a murine model of heart failure as well as the effects of XOIs on that process. We conclude that significant ventricular geometric remodeling occurs 4 wk after permanent coronary ligation in the mouse as evidenced by a doubling in LV mass, severalfold increases in EDV and ESV, as well as a marked reduction in LV EF (Table 1). The magnitude of these changes is comparable or larger than observed in other species (36). Less dramatic changes in mass, chamber dimensions, and EF have been reported in mice after reperfused infarction (50) and...
earlier than 4 wk after permanent coronary ligation (13). Less remodeling was also observed in other studies (30) where smaller infarct sizes (18 ± 2%) were induced than in this study (~50%), likely due to more proximal coronary ligation in our approach. The decrease in the ratio of LV mass to chamber volume is similar to that reported in other models with large infarctions after coronary occlusion (36, 38).

In addition, we observed a significant 30% reduction in the in vivo myocardial PCr/ATP in infarcted hearts. These data demonstrate that metabolic remodeling, at least in relation to the CK reaction, occurs in vivo in the postinfarction, failing mouse, and they are in agreement with prior observations (23, 29, 49) in patients and in larger animals after infarction. Taken together, they demonstrate that remodeling occurs in the mouse and suggest that transgenic murine lines may offer novel avenues for investigating additional mechanisms underlying postinfarction anatomic and energetic remodeling.

Marbán’s laboratory (43) recently showed that XO activity is increased in this mouse infarction model and that oral allopurinol suppresses this increase and improves both in vitro and in vivo contractile function as well as survival. The current MRI findings in different animals confirm the prior observation made with echocardiography that XO inhibition improves in vivo contractile function after infarction in the mouse and does so without preventing hypertrophy. In the earlier work, the improved contractile function with XOI was not associated with increased activator calcium or a left shift in calcium sensitivity but rather was due to an increase in force production during maximal calcium activation (43). Because allopurinol restored myofilament force generation to near-normal values without altering intracellular [Ca\(^{2+}\)], the hypothesis was generated that XO inhibition improves the poor coupling between energy production and mechanics in failing hearts. Simply put, the ability to generate more force without augmenting activator calcium predicts an improved efficiency of myocardial energy utilization.

Energy metabolism fuels normal myocardial contractile function, and for decades it has been hypothesized that a deficit in energy metabolism may contribute to the contractile deficit in heart failure (21, 22). Likewise, a deficit in energy metabolism could contribute to the progressive dysfunction and geometric changes after infarction (29). The CK reaction reversibly converts the major cardiac form of chemical energy ATP with the prime energy reserve metab-
olite PCr. Animal models of heart failure and patients with heart failure typically exhibit abnormalities in the CK react-

ants with modest reductions in [ATP], larger reductions in 
[PCr] and total creatine, and significant reductions in the 
cardiac PCr/ATP (4, 10, 15, 16, 29, 34). Abnormalities, such 
as a reduced PCr/ATP, correlate with the severity of the 
heart failure, improve with clinical recovery, and are stron-
ger predictors of mortality than usual clinical indexes of LV 
EF and the New York Heart Association class (31). All of 
these observations are consistent with but do not prove that 
the abnormalities in energy metabolism may contribute to 
the pathophysiology of the contractile dysfunction in heart 
failure. To test the energy starvation hypothesis of heart 
failure, one needs to determine whether a metabolic inter-
vention that improves energetics results in improved con-
tractile function in failing hearts. Evidence that overexpres-
sion of a glucose transporter in pressure-overload mice 
attenuates the development of heart failure (24) and that 
ranolizine, a free fatty-acid inhibitor, improves mechanical 
efficiency in dogs with heart failure (9) both indicate that 
metabolic interventions can be important in heart failure. 
However, here the energetic changes may be secondary to 
improved excitation-contraction coupling, rather than re-

flecting a primary metabolic effect.

In this regard, the current studies on XO inhibition in 
remodeled mouse myocardium provide important insights. XO 
inhibition improves mechanoenergetic coupling in failing 
hearts by reducing energetic demand in both animals and 
people (7, 11). Improved mechanoenergetic efficiency with XO 
inhibition occurs in failing but not normal hearts and is due to 
a reduction in myocardial oxygen consumption while main-
taining or improving contractile function. Thus XO inhibition 
represents one strategy for evaluating the energy starvation 
hypothesis of heart failure.

Why is the cardiac PCr/ATP lower in remodeled failing 
myocardium, and what is the mechanism by which XO inhi-
bition improves it? Myocardial PCr/ATP falls acutely during 

![Graph showing PCr/ATP values in control and MI mice with or without XO inhibition](image)

**Fig. 3.** In vivo PCr/ATP values in chest muscle (left) and cardiac muscle (right) from control (white bars, n = 10), MI (black bars, n = 9), MI+XOIs (gray bars, n = 10) mice. *P < 0.02, statistically significant difference with control group (normal mice); #P < 0.02, statistically significant difference with MI group.

ment in cardiac PCr/ATP with XOI is not likely due to an 
effect on infarct size because it is similar in control and 
infarcted hearts (Ref. 43, and see RESULTS) and because in-
farcted tissue does not contain significant PCr or ATP (45, 48). 
XOI is one of the first metabolic interventions that normalize 
reduced cardiac energetics in any model of heart failure. 
Moreover, improved energetics with XO inhibitors are associ-
ated with improved contractile function (EF, Table 1). Al-
though angiotensin-converting enzyme (ACE) inhibition pre-
vents the decrease of in vitro CK activity in infarcted rat hearts 
(17), ACE inhibition has many effects including those on LV 
hypertrophy and cardiac demand that can secondarily affect 
metabolism. Thus XO inhibition represents a metabolic ap-
proach to improve altered energetics after infarction in a failing 
heart, and this is associated with a significant improvement in 
contractile function in that setting.

**Fig. 4.** Relationship between end-systolic volume [ESV, A, where ESV = −130.63 (PCr/ATP) + 354.64; r = −0.7], end-diastolic volume [EDV, B, where EDV = −133.76 (PCr/ATP) + 384.2; r = −0.7], and ejection fraction [EF, C, where EF = 12.761 (PCr/ATP) − 0.821; r = 0.65] and myocardial PCr/ATP in MI (○) and MI+XOI (■) hearts.

**XANTHINE OXIDASE INHIBITORS AND CARDIAC ENERGETICS**

_AJP-Heart Circ Physiol • VOL 290 • FEBRUARY 2006 • www.ajpheart.org_
ischemia as a result of an imbalance of oxygen supply and demand whereby PCR is consumed to buffer or delay a decline in ATP. In the more chronic setting of heart failure, there is evidence that classic ischemia is not present in that deoxymyoglobin cannot be detected in several animal models of heart failure (2, 28). However, a slow loss in ATP does occur in heart failure that is accompanied by a more rapid and greater loss of total creatine (42). Creatine depletion acts to attenuate or prevent an increase in ADP as ATP falls (42). Because creatine is not synthesized in muscle cells, if expression of the major creatine transport proteins in animal models and patients with heart failure is depressed (35), then this may be the likely mechanism for the decrease in total creatine in heart failure. It seems likely that by improving mechanoenergetic coupling in dysfunctional myocardium and/or blocking adenine nucleotide degradation, XO inhibition attenuates the initial ATP loss and the resultant more dramatic decline in PCR/ATP. An alternative explanation posits that XOIs fundamentally alter cross bridge kinetics, such that more force is generated per ATP consumed. Such a mechanism has been proposed to underlie the effects of agents, such as XOIs, that increase maximal calcium-activated force without shifting the calcium-force relationship (39). We cannot exclude the possibility that XO inhibition exerts an antioxidant protective effect in the heart. The present data do not distinguish among these various mechanisms, which merit further discussion.

In conclusion, geometric, functional, and metabolic remodeling occurs in this mouse postinfarction model, and the magnitude of the changes is similar or greater than those observed in other larger mammals. XO inhibition attenuates but does not prevent the geometric changes, significantly improves contractile function, and completely normalizes depressed energy starvation hypothesis of heart failure. The widespread clinical availability of XO inhibitors should speed clinical trials of the metabolic and functional effects of XO inhibition in other models of heart failure are warranted. The observation that a metabolic intervention normalizes energetics and results in improved contractile function directly supports the long-debated energy starvation hypothesis of heart failure. The widespread clinical availability of XO inhibitors should speed clinical trials of the metabolic and functional effects of XO inhibition in human heart failure. Those trials would ultimately determine whether XO inhibition represents an additional therapeutic option to complement ACE inhibitors, β-blockers, and aldosterone inhibitors after infarction.

ACKNOWLEDGMENTS
We thank Michelle Leppo for performing MI surgery on the mice. Present address: A. Naumova: University of Washington, 815 Mercer St., Office 131A, Seattle, WA 98109; Present name and address of L. Stull: Linda Marbán, Excigen, Inc., 2415 Old Bosley Rd., Lutherville, MD 21093.

GRANTS
This work was supported by National Heart, Lung, and Blood Institute Grant HL-63030 (to R. G. Weiss) and R01-HL-44065 (to E. Marbán).

DISCLOSURES
E. Marbán holds the Michel Mirowsky, MD Professorship of Cardiology of the Johns Hopkins University. Under a licensing agreement between Cardiome Pharma Corporation and the Johns Hopkins University, E. Marbán is entitled to a share of royalty received by the University on sales of products described in this article. E. Marbán and the University own Cardiome Pharma Corporation stock, which is subject to certain restrictions under University policy. E. Marbán is a paid member of the Cardiome Pharma Corporation Scientific Advisory Board. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

REFERENCES


